CXCL8

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

Retrieved on: 
Monday, March 18, 2024
CCL7, COVID, Major, BMJ Open, IL-6, AKI, Inflammation, Lung, Biomarker, Hospital, Acute respiratory distress syndrome, TMX Group, CXCL10, Acute kidney injury, SARS-CoV-2, Human, TSX, Chemokine, Arch, Cytokine, Periodic breathing, Phase, OTCQB, CXCL8, Liver, Somayaji, BMJ, Randomness, Pharmaceutical industry

New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.

Key Points: 
  • New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.
  • Arch is currently performing a Phase II human trial to support LSALT peptide as a first ever treatment for preventing cardiac surgery-associated acute kidney injury.
  • The results of the Phase II trial provided first-ever evidence validating DPEP-1 as a mediator of organ inflammation and therapeutic target in humans.
  • The new data provides more scientific rationale for Arch to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications, including a larger Phase II trial targeting cardiac surgery-associated AKI, which recently began recruiting patients.

NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial

Retrieved on: 
Thursday, March 7, 2024
Queen Square, Doctor of Philosophy, Aes, TREM, CXCL8, CXCL1, Blood, IL-6, Cerebrospinal fluid, Inflammation, Neuroinflammation, NLRP3, Șaeș, Fibrinogen, Volunteering, Risk, Human, Biomarker, AFL, CRP, Patient, Pharmacokinetics, Disease, DSM-IV codes, MRCP, MBBS, Brain, CCL2, Mouse, Face, Pharmaceutical industry

IL-1β, IL-6, CCL2, CXCL1 and CXCL8) over 28 days compared to baseline to levels approximating those of healthy elderly controls, demonstrating reversal of NLRP3-mediated neuroinflammation.

Key Points: 
  • IL-1β, IL-6, CCL2, CXCL1 and CXCL8) over 28 days compared to baseline to levels approximating those of healthy elderly controls, demonstrating reversal of NLRP3-mediated neuroinflammation.
  • In addition, reductions in neurodegenerative markers were also observed following oral dosing of NT-0796, including NfL and soluble TREM (sTREM2).
  • The correlation between Parkinson’s disease and neuroinflammation is well-documented, with alpha-synuclein fibrils triggering microglial NLRP3 activation, leading to neuroinflammation and subsequent neurodegeneration.
  • This is the inaugural demonstration of an NLRP3 inhibitor’s potential to not only address Parkinson’s disease but also offer a broader impact on neurodegenerative diseases.

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

Retrieved on: 
Thursday, June 29, 2023
Maintenance, CELU, COL1A1, Type I collagen, Therapy, B cell, CTM, Disability, Pathology, Instituto de Biologia Molecular e Celular, MMP1, Research, Pain, Tendon cell, Regeneration, SCX, Rupture, International Conference on Information Systems Security and Privacy, COL3A1, Patient, Extracellular matrix, CXCL8, TNC, Collagen, type III, alpha 1, Phenotype, III, Conference, Logging, Vaccine, Orthopedic surgery

FLORHAM PARK, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company will present data from a new product technology in development for orthopedic applications at the upcoming 7th International Conference on Orthopedics, July 19th – 20th in Rome.

Key Points: 
  • FLORHAM PARK, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company will present data from a new product technology in development for orthopedic applications at the upcoming 7th International Conference on Orthopedics, July 19th – 20th in Rome.
  • As a result, the healed tendon often is mechanically incompetent and prone to degeneration and rupture.
  • “Celularity leverages a diversified portfolio of therapeutic technologies all derived from a single source material — the post-partum placenta.
  • These early tenocyte data are an important demonstration of our ongoing commitment and focus on innovation leveraging the placental platform we have pioneered.”

AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell

Retrieved on: 
Thursday, March 24, 2022
Private Securities Litigation Reform Act, Company, Cancer, PSLRA, Therapy, Date, Roswell Park Comprehensive Cancer Center, CCL5, TME, NYSE, PCR, CXCL8, CXCL10, Tumor microenvironment, AACR, Research, Doctor of Philosophy, Breast, CDT, American Association, Probability, CXCL9, Tissue, Rintatolimod, ELISA, Chemokine, American, Immunology, Association, American Association for Cancer Research, Paclitaxel, Taxane, Macrophage, CXCL11, TLR3, TaqMan, COVID-19, CTL, GLOBE, Breast cancer, Degenerative disease, CKM, Time, Lists of diseases, NK, CCL22, Patient, Disease, AIM, Medical imaging, Vaccine, MD

Our current data highlight thepotential for the chemokine modulatory regimen to enhance the effectiveness of taxane-based chemotherapy of breast cancer and potentially other diseases.

Key Points: 
  • Our current data highlight thepotential for the chemokine modulatory regimen to enhance the effectiveness of taxane-based chemotherapy of breast cancer and potentially other diseases.
  • Unexpectedly, paclitaxel treatment resulted in further elevation of granulocyte/MDSC-attractant CXCL8 and CCL22, which was reversed by the combination of paclitaxel with the CKM including Ampligen.
  • Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

Retrieved on: 
Friday, November 12, 2021
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Solar cycle 4, SITC, CXCL3, Cancer, Biopsy, Partial, CXCL8, Private Securities Litigation Reform Act, Form 10-K, Observation, Solar cycle 18, Neoplasm, PSA, Cytokine, Therapeutic index, Prostate cancer, Clinical trial, MCRPC, Abdominal wall, Security (finance), NASDAQ, CD8, Technology, Clinical Ovarian Cancer & Other Gynecologic Malignancies, RCC, Society, Trial of the century, Nivolumab, Serum, PD-1, Renal cell carcinoma, Forward-looking statement, CRPC, Annual report, Protein, U.S. Securities and Exchange Commission, IL-6, Large-cell lung carcinoma, Therapy, Degenerative disease, History, Pharmacodynamics, Prostate-specific antigen, Atrial fibrillation, Immunotherapy, Pancreas, IL-8, Patient, Melanoma, RECIST, Vaccine, Medical imaging, Pharmaceutical industry, Vudalimab (XmAb®717), Xencor, Inc., VUDALIMAB (XMAB®717), XENCOR, INC.

Dual targeting of these checkpoints through a bispecific antibody with a differentiated tolerability profile could meet an important unmet clinical need.

Key Points: 
  • Dual targeting of these checkpoints through a bispecific antibody with a differentiated tolerability profile could meet an important unmet clinical need.
  • We are now enrolling a Phase 2 study of vudalimab for patients with metastatic castration-resistant prostate cancer, as a monotherapy or in combination, depending on molecular subtype.
  • Baseline serum levels of the cytokines IL-6, IL-8 and IL-10 trended lower in patients who achieved a response on study.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.